Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb Trial

NCT01630018 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer

Interventions

DRUG: Topotecan
DRUG: Belotecan

Sponsor

Chong Kun Dang Pharmaceutical